American Bio Medica Corp (ABMC) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
122 SMITH ROAD KINDERHOOK, NY 12106 |
| State of Incorp. | NY |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 34 | 10 | 2 | 17 | 115 | 41 | |||
| Cash and cash equivalent | 34 | 10 | 2 | 17 | 115 | 41 | |||
| Receivables | 82 | 39 | 83 | 138 | 323 | 545 | |||
| Inventory, net of allowances, customer advances and progress billings | 379 | 380 | 401 | 419 | 443 | 419 | |||
| Inventory | 379 | 380 | 401 | 419 | 443 | 419 | |||
| Other undisclosed current assets | 274 | 241 | 256 | 464 | 459 | 604 | |||
| Total current assets: | 769 | 670 | 742 | 1,038 | 1,340 | 1,609 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 13 | ||||||||
| Property, plant and equipment | 466 | 479 | 491 | 504 | 517 | 529 | |||
| Intangible assets, net (including goodwill) | (206) | 102 | |||||||
| Intangible assets, net (excluding goodwill) | (206) | 102 | |||||||
| Other noncurrent assets | 21 | 21 | 21 | 21 | 21 | 21 | |||
| Other undisclosed noncurrent assets | 7 | 2 | 2 | 211 | 14 | ||||
| Total noncurrent assets: | 500 | 507 | 514 | 527 | 543 | 666 | |||
| TOTAL ASSETS: | 1,269 | 1,177 | 1,256 | 1,565 | 1,883 | 2,275 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,168 | 1,130 | 1,045 | 936 | 1,059 | 750 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | ✕ | 25 | |||
| Taxes payable | ✕ | ✕ | ✕ | ✕ | ✕ | 185 | |||
| Employee-related liabilities | ✕ | ✕ | 90 | 80 | 93 | 97 | 83 | ||
| Accounts payable | 760 | 950 | 885 | 843 | 682 | 667 | |||
| Accrued liabilities | 408 | 90 | 80 | 70 | |||||
| Debt | 2,230 | 1,240 | 1,240 | 1,240 | 1,543 | 1,736 | |||
| Deferred compensation liability | 109 | 79 | |||||||
| Other liabilities | 90 | 38 | |||||||
| Other undisclosed current liabilities | 5 | 822 | 677 | 695 | 105 | 502 | |||
| Total current liabilities: | 3,602 | 3,192 | 2,962 | 2,871 | 2,824 | 2,988 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 2 | 3 | 13 | ||||||
| Liabilities, other than long-term debt | 6 | ||||||||
| Operating lease, liability | 6 | 2 | 3 | 13 | |||||
| Other undisclosed noncurrent liabilities | 7 | 2 | (2) | (3) | |||||
| Total noncurrent liabilities: | 6 | 7 | 2 | 2 | 13 | ||||
| Total liabilities: | 3,608 | 3,199 | 2,964 | 2,873 | 2,827 | 3,001 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (2,339) | (2,022) | (1,708) | (1,308) | (944) | (726) | |||
| Common stock | 481 | 481 | 481 | 481 | 476 | 449 | |||
| Additional paid in capital | 22,403 | 22,403 | 22,403 | 22,403 | 23,393 | 22,313 | |||
| Accumulated deficit | (25,223) | (24,906) | (24,592) | (24,192) | (23,813) | (23,488) | |||
| Other undisclosed equity, attributable to parent | (1,000) | ||||||||
| Total equity: | (2,339) | (2,022) | (1,708) | (1,308) | (944) | (726) | |||
| TOTAL LIABILITIES AND EQUITY: | 1,269 | 1,177 | 1,256 | 1,565 | 1,883 | 2,275 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 167 | 209 | 185 | 351 | 509 | 614 | ||
| Cost of revenue | (307) | (218) | (258) | (323) | (386) | (429) | ||
| Other undisclosed gross profit | 90 | |||||||
| Gross profit: | (50) | (9) | (73) | 28 | 123 | 185 | ||
| Operating expenses | (1,139) | (253) | (274) | (359) | (345) | (389) | ||
| Operating loss: | (1,189) | (262) | (347) | (331) | (222) | (204) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (15) | (52) | (51) | (48) | (103) | 867 | ||
| Interest and debt expense | (41) | (53) | (52) | (48) | 335 | |||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 734 | 53 | 52 | 48 | (335) | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | (511) | (314) | (398) | (379) | (325) | 663 | ||
| Other undisclosed income from continuing operations before income taxes | 194 | |||||||
| Income (loss) from continuing operations before income taxes: | (317) | (314) | (398) | (379) | (325) | 663 | ||
| Income tax expense | (4) | (2) | ||||||
| Income (loss) from continuing operations: | (321) | (314) | (400) | (379) | (325) | 663 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | (314) | (400) | (379) | (325) | 663 | |
| Other undisclosed net income | 638 | 758 | ||||||
| Net income (loss): | 317 | (314) | (400) | 379 | (325) | 663 | ||
| Other undisclosed net loss attributable to parent | (634) | (758) | ||||||
| Net income (loss) available to common stockholders, diluted: | (317) | (314) | (400) | (379) | (325) | 663 | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 317 | (314) | (400) | 379 | (325) | 663 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 317 | (314) | (400) | 379 | (325) | 663 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.